Table 1. Baseline characteristics of the three cohorts of patients treated with immune checkpoint blockers alone (ICBs), ICBs in combination with chemotherapy (CT-ICBs) or CT alone (CT).
| Characteristic | ICBsN=126* | CT-ICBsN=66* | CTN=195* | P value† |
| Sex | 0.7 | |||
| Female | 49 (39) | 22 (33) | 74 (38) | |
| Male | 77 (61) | 44 (67) | 120 (62) | |
| Bone metastasis (yes) | 52 (41) | 33 (50) | 73 (38) | 0.2 |
| Liver metastasis (yes) | 17 (13) | 10 (15) | 24 (12) | 0.8 |
| Brain metastasis (yes) | 34 (27) | 24 (36) | 36 (19) | 0.010 |
| ECOG PS | 0.012 | |||
| 0–1 | 93 (74) | 46 (71) | 164 (85) | |
| ≥2 | 33 (26) | 19 (29) | 29 (15) | |
| Unknown | 0 | 1 | 1 | |
| Age | 67 (58–73) | 63 (56–70) | 61 (54–68) | 0.001 |
| Smocking habits | 0.6 | |||
| current/former | 113 (90) | 62 (94) | 179 (93) | |
| Never | 12 (9.6) | 4 (6.1) | 14 (7.3) | |
| Unknown | * | 0 | 3 | |
| PD-L1 TPS | 0.005 | |||
| 0% | 32 (27) | 24 (41) | 25 (53) | |
| 1–49% | 31 (26) | 19 (33) | 9 (19) | |
| ≥50% | 56 (47) | 15 (26) | 13 (28) | |
| Unknown | 7 | 8 | 149 | |
| LDH | >0.9 | |||
| ≤ULN | 82 (68) | 41 (67) | 106 (66) | |
| >ULN | 39 (32) | 20 (33) | 55 (34) | |
| Unknown | 5 | 5 | 33 | |
| Number of metastatic sites | 2.00 (1.00–3.00) | 3.00 (2.00–4.00) | 1.00 (1.00–2.00) | <0.001 |
| dNLR | 2.9 (2.0–4.5) | 4.0 (2.6–6.7) | 2.7 (1.7–7.3) | 0.005 |
| Histology | <0.001 | |||
| Non-squamous | 91 (72) | 56 (85) | 176 (91) | |
| Squamous | 35 (28) | 10 (15) | 18 (9.3) | |
| Line of treatment | ||||
| First line | 45 (36) | 66 (100) | 195 (100) | |
| Advanced lines | 81 (64) | 0 | 0 | |
| Unique peptide seropositivity count | 277 (219–368) | 261 (211–329) | 351 (260–450) | <0.001 |
*
n (%); Mmedian (IQR).
†
Pearson’s Chi-squaredχ2 test; Kruskal-Wallis rank sum test.
dNLR, derived neutrophil to lymphocyte ratioLDH, lactate dehydrogenase; PD-L1programmed death-ligand 1 PS, Eastern Cooperative Oncology Group performance status; TPS, tumor proportion score; ULN, upper limit of normality